Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Filings indexed 372 across all filing types
Latest filing 2021-03-25 Annual Report
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2020
2021-03-25 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 25, 2021, reporting the company's audited financial results for the year ended December 31, 2020. It includes a press release titled '4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights.' The document is relatively short (3695 characters) and primarily serves to announce the financial results via a press release rather than containing the full detailed financial statements or comprehensive analysis. According to the rules, such a document is best classified as an Earnings Release (ER) since it is the initial announcement of periodical financial results with key highlights, not the full annual report or detailed management discussion.
2021-03-25 English
FORM 4
Director's Dealing
2021-03-10 English
FORM 4
Director's Dealing
2021-03-10 English
FORM 4
Director's Dealing
2021-03-10 English
SCHEDULE 13G/A
Major Shareholding Notification
2021-02-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.